Phaseline

Targets › HER2

HER2 (Receptor tyrosine-protein kinase erbB-2): drug programs, companies and trials

9 programs from 9 companies in 10 trials: 9 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. (UniProt, P04626)

Open in Phaseline: the race on HER2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of WashingtonpUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine (WOKVAC)
Plasmid DNA vaccine encoding tumor-associated antigens (IGFBP2, HER2, IGF1R) to stimulate
IGFBP2, HER2, IGF1RPhase 2Anatomic Stage I Breast Cancer AJCC v8Dec 2026
City of Hope Medical CenterHER2(EQ)BBζ/CD19t+ T cells
CAR-T cell therapy targeting HER2 with co-stimulatory BBζ domain and CD19 marker
HER2Phase 1GlioblastomaDec 2026
Beijing BiotechEB-DUO-CAR-NK-CEA/GCC
Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H
CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15Phase 1Colorectal Cancer; Colorectal Cancer MetastaticMar 2027
Changchun GeneScience PharmaceuticalGenSci139
bispecific antibody drug conjugate targeting EGFR and HER2
EGFR, HER2Phase 1Advanced Solid TumorsJul 2028
BayerBAY2927088 (sevabertinib)
Tyrosine kinase inhibitor targeting mutated EGFR and HER2
EGFR, HER2Phase 1Advanced Non-small Cell Lung CancerDec 2028
BlossomHill TherapeuticsBH-30643
Dual EGFR/HER2 inhibitor
EGFR, HER2Phase 1NSCLC (Advanced Non-small Cell Lung Cancer)Jan 2029
University of VirginiaHER2 FPBMC
Anti-CD3 x anti-HER2 bispecific antibody armed fresh peripheral blood mononuclear cells
HER2, CD3Phase 1Breast CancerOct 2029
Pierre Fabre MedicamentSTX-721/PFL-721
Exon 20 insertion-selective tyrosine kinase inhibitor
EGFR, HER2Phase 1Non-Small Cell Lung CancerDec 2029
Vanderbilt-Ingram Cancer Center[18F]NOTA-ABY-030
HER2-targeted PET imaging agent; anti-HER2 Affibody molecule labeled with fluorine-18
HER2Phase 1HNSCC,Larynx, Pharynx and Oral CavityJul 2031

Conditions

Breast Cancer (1) HNSCC,Larynx, Pharynx and Oral Cavity (1) Colorectal Cancer (1) Colorectal Cancer Metastatic (1) NSCLC (Advanced Non-small Cell Lung Cancer) (1) Non-Small Cell Lung Cancer (1) Anatomic Stage I Breast Cancer AJCC v8 (1) Advanced Non-small Cell Lung Cancer (1) Glioblastoma (1) Advanced Solid Tumors (1)

Modalities

small molecule (5), mixed (3), other (1)

Companies

University of Virginia (1) Vanderbilt-Ingram Cancer Center (1) Beijing Biotech (1) BlossomHill Therapeutics (1) Pierre Fabre Medicament (1) University of Washington (1) Bayer (1) City of Hope Medical Center (1) Changchun GeneScience Pharmaceutical (1)

Related targets

EGFR (4) CD3 (1) CEACAM5 (1) GUCY2C (1) ERBB2 (1) CEA (1) IL15 (1) IGFBP2 (1) IGF1R (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.